期刊文献+

Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes 被引量:78

Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes
在线阅读 下载PDF
导出
摘要 AIM To review Hepatitis C virus(HCV) prevalence and genotypes distribution worldwide.METHODS We conducted a systematic study which represents one of the most comprehensive effort to quantify global HCV epidemiology,using the best available published data between 2000 and 2015 from 138 countries(about 90% of the global population),grouped in 20 geographical areas(with the exclusion of Oceania),as defined by the Global Burden of Diseases project(GBD). Countries for which we were unable to obtain HCV genotype prevalence data were excluded from calculations of regional proportions,although their populations were included in the total population size of each region when generating regional genotype prevalence estimates.RESULTS Total global HCV prevalence is estimated at 2.5%(177.5 million of HCV infected adults),ranging from 2.9% in Africa and 1.3% in Americas,with a global viraemic rate of 67%(118.9 million of HCV RNA positive cases),varying from 64.4% in Asia to 74.8% in Australasia. HCV genotype 1 is the most prevalent worldwide(49.1%),followed by genotype 3(17.9%),4(16.8%) and 2(11.0%). Genotypes 5 and 6 are responsible for the remaining < 5%. While genotypes 1 and 3 are common worldwide,the largest proportion of genotypes 4 and 5 is in lower-income countries. Although HCV genotypes 1 and 3 infections are the most prevalent globally(67.0% if considered together),other genotypes are found more commonly in lowerincome countries where still account for a significant proportion of HCV cases.CONCLUSION A more precise knowledge of HCV genotype distribution will be helpful to best inform national healthcare models to improve access to new treatments. AIM To review Hepatitis C virus(HCV) prevalence and genotypes distribution worldwide.METHODS We conducted a systematic study which represents one of the most comprehensive effort to quantify global HCV epidemiology,using the best available published data between 2000 and 2015 from 138 countries(about 90% of the global population),grouped in 20 geographical areas(with the exclusion of Oceania),as defined by the Global Burden of Diseases project(GBD). Countries for which we were unable to obtain HCV genotype prevalence data were excluded from calculations of regional proportions,although their populations were included in the total population size of each region when generating regional genotype prevalence estimates.RESULTS Total global HCV prevalence is estimated at 2.5%(177.5 million of HCV infected adults),ranging from 2.9% in Africa and 1.3% in Americas,with a global viraemic rate of 67%(118.9 million of HCV RNA positive cases),varying from 64.4% in Asia to 74.8% in Australasia. HCV genotype 1 is the most prevalent worldwide(49.1%),followed by genotype 3(17.9%),4(16.8%) and 2(11.0%). Genotypes 5 and 6 are responsible for the remaining < 5%. While genotypes 1 and 3 are common worldwide,the largest proportion of genotypes 4 and 5 is in lower-income countries. Although HCV genotypes 1 and 3 infections are the most prevalent globally(67.0% if considered together),other genotypes are found more commonly in lowerincome countries where still account for a significant proportion of HCV cases.CONCLUSION A more precise knowledge of HCV genotype distribution will be helpful to best inform national healthcare models to improve access to new treatments.
出处 《World Journal of Gastroenterology》 SCIE CAS 2016年第34期7824-7840,共17页 世界胃肠病学杂志(英文版)
关键词 HEPATITIS C VIRUS genotype EPIDEMIOLOGY HEPATITIS C VIRUS HEPATITIS C VIRUS prevalence HEPATITIS C VIRUS infections VIRAEMIA Hepatitis C virus genotype Epidemiology Hepatitis C virus Hepatitis C virus prevalence Hepatitis C virus infections Viraemia
  • 相关文献

参考文献71

  • 1Natasha K. Martin,Matthew Hickman,Sharon J. Hutchinson,David J. Goldberg,Peter Vickerman.??Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy(J)Clinical Infectious Diseases . 2013 (supp)
  • 2V. D. HOPE,I. ERAMOVA,D. CAPURRO,M. C. DONOGHOE.Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association[J].Epidemiology and Infection.2013(2)
  • 3Eric Lawitz,Fred F Poordad,Phillip S Pang,Robert H Hyland,Xiao Ding,Hongmei Mo,William T Symonds,John G McHutchison,Fernando E Membreno.Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial[J]. The Lancet . 2013
  • 4Homie Razavi,Antoine C. ElKhoury,Elamin Elbasha,Chris Estes,Ken Pasini,Thierry Poynard,Ritesh Kumar.??Chronic hepatitis C virus (HCV) disease burden and cost in the United States(J)Hepatology . 2013 (6)
  • 5Petruzziello, Arnolfo,Coppola, Nicola,Diodato, Anna Maria,Iervolino, Vincenzo,Azzaro, Rosa,Di Costanzo, Gaetano,Di Macchia, Catia Addolorata,Di Meo, Tommaso,Loquercio, Giovanna,Pasquale, Giuseppe,Cacciapuoti, Carmela.??Age and Gender Distribution of Hepatitis C Virus Genotypes in the Metropolitan Area of Naples(J)Intervirology . 2013 (3)
  • 6Denniston MM,Jiles RB,Drobeniuc J,Klevens RM,Ward JW,Mc Quillan GM,Holmberg SD.Chronic hepatitis C virus infection in the United States,National Health and Nutrition Examination Survey 2003 to 2010. Annals of Internal Medicine . 2014
  • 7The Global Burden of Hepatitis C Working Group.Global Burden of Disease (GBD) for Hepatitis C. The Journal of Clinical Pharmacology . 2004
  • 8Nathan Ford,Kasha Singh,Graham S Cooke,Edward J Mills,Tido von Schoen-Angerer,Adeeba Kamarulzaman,Philipp du Cros.Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/ AIDS. Clinical Infectious Diseases . 2012
  • 9Liakina V,Hamid S,Tanaka J,Olafsson S,Sharara AI,Alavian SM,Gheorghe L,El Hassan ES,Abaalkhail F,Abbas Z,Abdou A,Abourached A,Al Braiki F,Al Hosani F,Al Jaberi K,Al Khatry M,Al Mulla MA,Al Quraishi H,Al Rifai A,Al Serkal Y,Alam A,Alashgar HI,Alawadhi S,Al.Historical epidemiology of hepatitis C virus(HCV)in select countriesvolume 3. Journal of Viral Hepatitis . 2015
  • 10Godzik P,Ko?akowska A,Madaliński K,StepieńM,Zieliński A,Góralewska A,Kazimierska M,Kunc-Kozio?R,Nadolska B,Paw?owska A,Piskorek A,Równiak J,Rosińska M.(Prevalence of anti-HCV antibodies among adults in Poland--results of crosssectional study in general population)Przeglad Epidemiologiczny . 2012

二级参考文献1

共引文献47

同被引文献320

引证文献78

二级引证文献229

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部